Trinity Biotech announces plan to implement ADS ratio change

Trinity Biotech announced that it plans to change the ratio of the American depositary shares representing its Class A ordinary shares from one ADS representing four Class A ordinary share to one ADS representing twenty Class A ordinary shares. For Trinity Biotech Plc ADS holders, the change in the ADS ratio will have the same effect as a one-for-five reverse ADS split and is intended to enable the Company to regain compliance with the $1.00 Nasdaq minimum bid price requirement, and facilitate investment from a broader pool of potential investors, who may have previously been unable to invest due to the ADSs trading below a price of $1.00. There is no change to the Company’s Class A ordinary shares. The effect of the ratio change on the ADS trading price on the Nasdaq Global Market is expected to take place at the open of trading on February 21, 2024.